The FDA is slated to announce its decision on Assertio Therapeutics Inc.’s (ASRT) New Drug Application for injectable formulation of long-acting Cosyntropin depot on October 19, 2019.The product, for which approval is sought under the 505(b)(2) regulatory pathway, is proposed as a diagnostic drug in the screening of patients presumed to have adrenocortical insufficiency.Long-acting Cosyntropin is an alcohol-free formulation of a synthetic analogue of ACTH, a hormone secreted from the pituitary gland that is responsible for the stimulation of the adrenal cortex. Cosyntropin is composed of the first 24 of 39 amino acids of natural ACTH, and retains the full steroidogenic activity of natural ACTH.Adrenal insufficiency, also called adrenocortical insufficiency or hypocortisolism, is a rare disorder in which the adrenal glands don’t produce enough hormones like cortisol and aldosterone.ASRT closed Friday’s (Sep.27, 2019) trading at $1.31, down 8.39%.